- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.08. | Profusa, Inc. reports Q2 results | 2 | Seeking Alpha | ||
| 20.08. | Profusa converts $4.6M debt to preferred stock ahead of G3 deal | 4 | Investing.com | ||
| 20.08. | Profusa, Inc.: Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company | 219 | GlobeNewswire (Europe) | Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of which $4.57 million was converted into Series A Convertible Preferred Stock Sufficient working... ► Artikel lesen | |
| 20.08. | Profusa, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 19.08. | Profusa, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| PROFUSA Aktie jetzt für 0€ handeln | |||||
| 13.08. | Profusa to implement 1-for-4 reverse stock split | 1 | Seeking Alpha | ||
| 13.08. | Profusa, Inc.: Profusa Announces 1-for-4 Reverse Stock Split | 563 | GlobeNewswire (Europe) | BERKELEY, California, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform... ► Artikel lesen | |
| 31.07. | Profusa, Inc.: Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs | 426 | GlobeNewswire (Europe) | BERKELEY, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of an Option Agreement... ► Artikel lesen | |
| 27.07. | Profusa Announces Signing Of Non-Binding Term Sheet For Acquisition Of Commercial-Stage Diagnostics Company | 2 | pulse2.com | ||
| 27.07. | Profusa inks term sheet to merge with $111M health diagnostics firm; appoints Jack Stover as CEO | 1 | Seeking Alpha | ||
| 27.07. | Profusa unterzeichnet Absichtserklärung zur Übernahme eines Diagnostikunternehmens | 2 | Investing.com Deutsch | ||
| 27.07. | Profusa signs term sheet to acquire diagnostics company | 1 | Investing.com | ||
| 27.07. | Profusa, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.07. | Profusa, Inc.: Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company | 330 | GlobeNewswire (Europe) | BERKELEY, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of a non-binding... ► Artikel lesen | |
| 06.07. | Profusa, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.07. | Profusa approves 1-for-25 reverse stock split; shares tumble | 1 | Seeking Alpha | ||
| 02.07. | Profusa kündigt Aktienzusammenlegung im Verhältnis 1:25 mit Wirkung zum 7. Juli an | 1 | Investing.com Deutsch | ||
| 02.07. | Profusa announces 1-for-25 reverse stock split effective July 7 | 1 | Investing.com | ||
| 02.07. | Profusa, Inc.: Profusa Announces 1-for-25 Reverse Stock Split | 178 | GlobeNewswire (Europe) | BERKELEY, California, July 02, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology... ► Artikel lesen | |
| 24.06. | Profusa, Inc.: Profusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance Efforts | 247 | GlobeNewswire (Europe) | BERKELEY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces that shareholders approved... ► Artikel lesen |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 5,330 | -1,81 % | BetterHelp Has the Demand: Can Teladoc Build the Capacity? | ||
| HIMS & HERS HEALTH | 25,920 | +1,17 % | Aktien New York: Chipwerte belasten Nasdaq - US-Pläne gegen Iran bewegen kaum | NEW YORK (dpa-AFX) - Technologieaktien haben am Montag in den USA erneut geschwächelt. Standardwerte legten dagegen überwiegend moderat zu. Negative Vorgaben aus Asien, die am Mittwoch nachbörslich... ► Artikel lesen | |
| CERENOME | 2,490 | -1,97 % | Cerenome, Inc.: Cerenome Reports Second Quarter 2026 Financial Results and Business Update | HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics... ► Artikel lesen | |
| HEALWELL AI | 0,476 | -1,96 % | HEALWELL AI: HEALWELL AI's DARWEN AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation | Pentavere advances from winning the 2024 Prix Galien USA Award to competing internationally among Prix Galien winners from around the world, further validating DARWEN AI as a globally recognized... ► Artikel lesen | |
| CO-DIAGNOSTICS | 1,255 | +0,40 % | Co-Diagnostics Reports Second Quarter 2026 Financial Results | Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion
Strengthening Integrated Co-Dx PCR Platform Through Scientific... ► Artikel lesen | |
| ORGANON | 11,720 | -0,80 % | Dividendenbekanntmachungen (14.08.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADM HAMBURG AG DE0007269003 - 13,58 EUR AGCO CORPORATION US0010841023 0,3 USD 0,2602 EUR AGNT INC US30212W1009 0,05 USD 0,0433... ► Artikel lesen | |
| VERU | 2,800 | 0,00 % | Veru Inc.: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress | -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients - -- Phase 2b PLATEAU clinical trial interim analysis and... ► Artikel lesen | |
| CLOVER HEALTH INVESTMENTS | 3,610 | -1,10 % | CLOVER HEALTH INVESTMENTS, CORP. /DE - 8-K, Current Report | ||
| SENSEONICS | 7,900 | -1,25 % | Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results | Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration... ► Artikel lesen | |
| ELEKTA | 4,784 | -2,92 % | Elekta AB: First quarter, May-July 2026/27 | First quarterRegions Americas and Europe showed solid growth while region APJ, China and TIMEA declined. In constant exchange rates, net sales decreased by 2 percent for the Group. Reported sales in... ► Artikel lesen | |
| IMUNON | 1,430 | +2,88 % | Imunon to host R&D day on Sept. 23 for ovarian cancer therapy | ||
| PERSPECTIVE THERAPEUTICS | 2,814 | +3,91 % | Perspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results | Advancing VMT-a-NET toward a Phase 3 study in neuroendocrine tumors, subject to regulatory alignment: regulatory engagement ongoing; clinical site activation targeted around year-end 2026 subject... ► Artikel lesen | |
| AXOGEN | 45,860 | +3,64 % | Truist stuft AxoGen mit "Buy" ein und verweist auf starkes Wachstumspotenzial | ||
| NIAGEN BIOSCIENCE | 2,700 | -4,93 % | Niagen Bioscience Aktie legt nach Vertriebsdeals mit GNC und Sam's Club zu - Canaccord bestätigt Kaufempfehlung | ||
| MYOMO | 1,262 | -4,83 % | Myomo expects $45M-$47M full-year revenue while targeting second-half cash burn below $2M |
PROFUSA INC gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 4,255 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROFUSA INC finden Sie auf Wallstreet Online.